Paul Wakim, PhD
Biostatistics and Clinical Epidemiology Service
BSc, University of Illinois, Urbana
MA, University of California, Berkeley
MS, University of California, Berkeley
PhD, University of California, Berkeley
Back to Senior Staff Directory
NIH Clinical Center Senior Staff
Paul Wakim, PhD
Dr. Paul Wakim is Chief of the Biostatistics and Clinical Epidemiology Service at the National Institutes of Health Clinical Center. Prior to joining the Clinical Center in 2015, he was Senior Mathematical Statistician at the Center for the Clinical Trials Network at the National Institute on Drug Abuse, where he was involved for almost 14 years in the design, statistical analysis, and monitoring of multi-site clinical trials.
Prior to joining NIDA, he worked in litigation at PricewaterhouseCoopers, in the Statistics Department of the American Petroleum Institute, and in the Statistical Research Division of the U.S. Census Bureau. He taught evening courses in Mathematics and Statistics at the University of Maryland University College, College Park, and at Gallaudet University, Washington, DC. He conducted several workshops and lectures at the NIH and at the annual meetings of the Society for Clinical Trials. He is currently a member of the Society for Clinical Trials Board of Directors (2015-2019).
Dr. Wakim received a B.Sc. in Mathematics from the University of Illinois at Urbana-Champaign. From the University of California at Berkeley, he received an M.A. in Statistics, an M.S. in Industrial Engineering and Operations Research and a Ph.D. in Statistics.
Honors and Awards
Received the NIH Director's Award in 2007 for contributing to the launch of the Clinical and Translational Science Award Program.
Guerrieri GM, Wakim PG, Keenan PA, Schenkel LA, Berlin K, Gibson CJ, Rubinow DR & Schmidt PJ. Sex differences in visuospatial abilities persist during induced hypogonadism. Neuropsychologia, 2016, 81:219-229
Lindblad R, Hu L, Oden N, Wakim P, Rosa C, VanVeldhuisen P. Mortality Rates Among Substance Use Disorder Participants in Clinical Trials: Pooled Analysis of Twenty-Two Clinical Trials Within the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment, 2016, 70:73-80
Hser Y-I, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P & Ling W. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction, 2016, 11: 695-705. doi: 10.1111/add.13238
Jacobs P, Ang A, Hillhouse MP, Saxon AJ, Nielsen S, Wakim PG, Mai BE, Mooney LJ, Potter JS & Blaine JD. Treatment Outcomes in Opioid Dependent Patients With Different Buprenorphine/Naloxone Induction Dosing Patterns and Trajectories, American Journal on Addictions, 2015, 24:667-675
Conway KP, Vullo GC, Kennedy AP, Finger MS, Agrawal A, Bjork JM, Farrer LA, Hancock DB, Hussong A, Wakim P, Huggins W, Hendershot T, Nettles DS, Pratt J, Maiese D, Junkins HA, Ramos EM, Strader LC, Hamilton CM & Sher KJ. Data compatibility in the addiction sciences: An examination of measure commonality, Drug and Alcohol Dependence, 2014, 141:152-158
Wakim PG, Rosa C, Kothari P & Michel ME. Relation of Study Design to Recruitment and Retention in CTN Trials, American Journal of Drug and Alcohol Abuse, 2011, 37:426-433
Potter JS, Donovan DM, Weiss RD, Gardin J, Lindblad R, Wakim P & Dodd D. Site Selection in Community-Based Clinical Trials for Substance Use Disorders: Strategies for Effective Site Selection, American Journal of Drug and Alcohol Abuse, 2011, 37:400-407
Korte JE, Rosa CL, Wakim PG & Perl HI. Addiction treatment trials: how gender, race/ethnicity, and age relate to ongoing participation and retention in clinical trials, Substance Abuse and Rehabilitation, 2011, 2:205-218
Donovan DM, Bigelow GE, Brigham GS, Carroll KM, Cohen AJ, Gardin JG, Hamilton JA, Huestis MA, Hughes JR, Lindblad R, Marlatt GA, Preston KL, Selzer JA, Somoza EC, Wakim PG & Wells EA. Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials, Addiction, 2011, 107: 694-708
Oden NL, VanVeldhuisen PC, Wakim PG, Trivedi MH, Somoza E & Lewis D. Power of Automated Algorithms for Combining Time-Line Follow-Back and Urine Drug Screening Test Results in Stimulant-Abuse Clinical Trials, American Journal of Drug and Alcohol Abuse, 2011, 37:350-357
Nunes EV, Ball S, Booth R, Brigham G, Calsyn DA, Carroll K, Feaster DJ, Hien D, Hubbard RL, Ling W, Petry NM, Rotrosen J, Selzer J, Stitzer M, Tross S, Wakim P, Winhusen T & Woody G. Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs?, Journal of Substance Abuse Treatment, 2010, 38 (Suppl 1):S97-S112
Brigham GS, Feaster DJ, Wakim PG & Dempsey CL. Choosing a control group in effectiveness trials of behavioral drug abuse treatments, Journal of Substance Abuse Treatment, 2009, 37:388-397
Wu L-T, Blazer DG, Patkar AA, Stitzer ML, Wakim PG & Brooner RK. Heterogeneity of Stimulant Dependence: A National Drug Abuse Treatment Clinical Trials Network Study, American Journal on Addictions, 2009, 18: 206-218
Pan J-J, Nahm M, Wakim P, Cushing C, Poole L, Tai B & Pieper CF. A centralized informatics infrastructure for the National Institute on Drug Abuse Clinical Trials Network, Clinical Trials, 2009, 6:67-75
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 07/06/2017